Q-omics provides the consensus-scored RPS2P48 profile across patient tissues and cancer cell-line models. RPS2P48 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPS2P48 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, RPS2P48 RNA expression shows 12,702 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KIRP, and ACC as cancer lineages where RPS2P48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS2P48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS2P48 survival associations across molecular data types. RPS2P48 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS2P48 RNA expression–survival associations across cancer types. High RPS2P48 expression shows unfavorable associations in LIHC, UCS, ACC and KIRP, but favorable associations in CESC and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPS2P48 RNA expression.
This table summarizes RPS2P48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPS2P48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS2P48 shows higher tumor expression in KIRP, COAD, KIRC, LUSC, LIHC and LUAD. The KIRP box plot shows higher RPS2P48 RNA expression in tumor versus normal tissue (log2 FC = +0.297, t-test p < 0.001).
This table shows molecular features associated with RPS2P48 in patient tissues and cancer cell lines. In patient samples, RPS2P48 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
